Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone.
- Resource Type
- Academic Journal
- Authors
- Crocetto F; Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy. Electronic address: felice.crocetto@unina.it.; Ferro M; Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy.; Buonerba C; Associazione O.R.A.-Oncology Research Assistance, 80049 Somma Vesuviana, Italy; Oncology Unit, 'Andrea Tortora' Hospital, ASL Salerno, 84016 Pagani, Italy.; Bardi L; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples 'Federico II', Naples, Italy.; Dolce P; Department of Public Health, Federico II University of Naples, Naples, Italy.; Scafuri L; Associazione O.R.A.-Oncology Research Assistance, 80049 Somma Vesuviana, Italy; Oncology Unit, 'Andrea Tortora' Hospital, ASL Salerno, 84016 Pagani, Italy.; Mirto BF; Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.; Verde A; Associazione O.R.A.-Oncology Research Assistance, 80049 Somma Vesuviana, Italy; Oncology Unit, 'Andrea Tortora' Hospital, ASL Salerno, 84016 Pagani, Italy.; Sciarra A; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, NA, Italy.; Barone B; Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.; Calogero A; Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples 80131, Italy.; Sagnelli C; Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania 'Luigi Vanvitelli', Naples 80138, Italy.; Busetto GM; Department of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.; Del Giudice F; Department of Maternal Infant and Urological Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy.; Cilio S; Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.; Sonpavde G; Division of Medical Oncology, Advent Health Cancer Institute, Orlando, FL, USA.; Di Trolio R; Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.; Della Ratta GL; Cardiology Unity, Humanitas Gavazzeni, Bergamo, Italy.; Barbato G; Department of Anesthesia and Intensive Care, 'Anastasia Guerriero' Hospital, Caserta Local Health Authority, Marcianise, Caserta, Italy.; Di Lorenzo G; Associazione O.R.A.-Oncology Research Assistance, 80049 Somma Vesuviana, Italy; Oncology Unit, 'Andrea Tortora' Hospital, ASL Salerno, 84016 Pagani, Italy; Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, 86100 Campobasso, Italy.
- Source
- Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE
- Subject
- Language
- English
Anti-VEGF (vascular endothelial growth factor) agents were associated with increased risk of several cardiovascular events, while one meta-analysis did not show any significantly increased risk of cardiotoxicity associated with the use of immune checkpoint inhibitors (ICIs). This meta-analysis of randomized-controlled trials (RCTs) was designed to compare cardiovascular toxicity of anti-VEGF agents plus ICI vs anti-VEGF agents without ICIs. A systematic search of the literature was conducted to include all full papers reporting about phase II and III randomized controlled trials (RCTs) conducted in patients with solid malignancies randomized to an anti-VEGF agent plus an ICI vs. an anti-VEGF agent without an ICI. Overall incidences of cardiovascular events were compared between these two treatment groups estimating the corresponding odds ratios. This analysis suggests that ICIs may increase the risk of cardiovascular toxicities associated with anti-VEGF therapies. Further research, including real world studies, is warranted.
Competing Interests: Declaration of Competing Interest
(Copyright © 2023 Elsevier B.V. All rights reserved.)